Trial Profile
Phase II evaluation of EMD121974 (NSC 707544, cilengitide) in asymptomatic patients with metastatic androgen independent prostate cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Cilengitide (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- 13 Jul 2012 Actual end date (1 Jan 2011) added as reported by CliniclaTrials.gov.
- 01 Jan 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 25 Apr 2010 Results published in Investigational New Drugs.